HK Inno.N and AstraZeneca Korea announced on the 31st that they held a signing ceremony at HK Inno.N's Seoul office to mark their strategic collaboration of their diabetes portfolio.

Under the agreement, HK Inno.N will jointly market and sell Xigduo (dapagliflozin + metformin) and Sidapvia (dapagliflozin + sitagliptin) with AstraZeneca Korea.

HK Inno.N had signed a co-promotion agreement for Sidapvia in October last year. The co-promotion agreement was expanded this time to include Xigduo.

At the same time, the company will be responsible for the domestic supply and distribution of the single-agent drug ‘Forxiga.’ At the end of last year, AstraZeneca Korea decided to wit